Navigation Links
Omeros Appoints David A. Mann to its Board of Directors
Date:8/13/2008

SEATTLE, Aug. 13 /PRNewswire/ -- Omeros Corporation has announced the appointment of David A. Mann to the Company's Board of Directors. Mr. Mann also serves as Chairman of the Board's audit committee.

"Dave's years of executive management experience in finance and operations in the biotechnology sector are an invaluable asset to Omeros," stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. "He is an important addition to our Board, and I expect that he will play an integral role as we prepare for product commercialization."

"Dr. Demopulos and his team have done an excellent job in advancing their PharmacoSurgery platform, and I am pleased to be working with them," commented David Mann. "With a deep pipeline focused on inflammation and CNS, Omeros represents an exciting opportunity."

Mr. Mann brings with him over 20 years of executive management, finance and operations experience in the biotechnology industry. He was executive vice president and chief financial officer at Immunex prior to and during its acquisition by Amgen, and held senior financial positions at the Fred Hutchinson Cancer Research Center. Mr. Mann serves on the Board of Directors of Trubion Pharmaceuticals, and is on the advisory board of the Western Washington University College of Business and Economics and the Western Washington University Foundation Board. He is a former Certified Public Accountant, and earned his M.B.A. from the University of Washington and a B.A. from Western Washington University.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other su
'/>"/>

SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. SpineMark Appoints Dr. Rudolf Bertagnoli Chairman of International Medical Advisory Board
4. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
5. SAFC Appoints New Vice President of Quality and Regulatory Affairs
6. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
7. ARCA biopharma Appoints James Carr as Vice President of Marketing
8. China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors
9. Health Monitoring Systems Appoints Karen S. Dockrell As VP, Sales
10. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
11. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... N.Y., Dec. 15 On January 20th, ... Society for Medical Publication Professionals (ISMPP) will be ... London, UK. More than 100 attendees are expected ... for publication professionals, editors, publishers, medical writers and ... medical publications and the impact of guidelines and ...
(Date:12/14/2009)... Dec. 14 Vermillion, Inc. (Pink ... announced William C. Wallen, Ph.D. Chief Scientific ... for IDEXX Laboratories, will be joining its ... bankruptcy plan. ,, "Bill brings more ... in diagnostics and biotechnology," said Gail Page, ...
(Date:12/14/2009)... Mass., Dec. 14 Lionbridge (Nasdaq: ... has signed a new, three-year master services ... with products and services that serve patients ... Lionbridge will become the sole provider for ... includes regulatory, marketing, training, human resources, legal, ...
(Date:12/11/2009)... EntreMed, Inc. (Nasdaq: ENMD ), today announced ... from sales of Thalomid® during the third quarter ... In addition, the Company anticipates a decrease ... 2009. The difference in estimated and actual ... in the fourth quarter financial results. ,, (Logo: ...
Breaking Biology Technology:Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3EntreMed Reports Receipt of Third Quarter Royalty Payment 2
... OAKLAND, Calif., June 23 (Nasdaq: ... that it has entered into a,Recapitalization Agreement ... owned subsidiary, World Heart Inc. ("WHI"), Abiomed, ... V, L.P. and,Venrock Entrepreneurs Fund V, L.P. ...
... Will Cover the Use of Pharsight Software for In-Vitro ... Correlation ... 23 Pharsight(R),Corporation (Nasdaq: PHST ), a leading ... clinical drug,development, today announced that Jason Chittenden, MS, Director ...
... released featuring the biotech industry in the ... BioSpace, the world,s leading,online bioscience job ... released,this morning the 2008-2009 BioMidwest(TM) Hotbed Campaign ... Michigan, Minnesota,Missouri, Nebraska, Ohio and Wisconsin., ...
Other Biology Technology:WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 2WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 3WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 4WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 5WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 6Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference 2Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference 3BioSpace Announces the 2008-2009 BioMidwest(TM) Hotbed Campaign 2
(Date:12/13/2009)... help to engineer plants that take advantage of elevated ... could help to engineer crops that take advantage of ... dioxide they need for photosynthesis through microscopic breathing pores ... of the gas gained, they lose hundreds of water ... to save water when CO 2 is abundant, ...
(Date:12/13/2009)... discovered five genetic variants that are associated with the ... international consortium of 96 scientists from 63 centres in ... basis of lung diseases. , The new findings provide ... Obstructive Pulmonary Disease (COPD) and asthma. In the past ... the molecular pathways that affect the health of the ...
(Date:12/11/2009)... consumer demand for premium fruit increases, growers are ... market. And to boost their bottom line, orchard ... increase fruit quality while reducing labor costs. , ... to produce larger, healthier fruit, is among the ... impact on fruit production overhead, and, ultimately, prices ...
Breaking Biology News(10 mins):Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3New genes for lung disease discovered 2Horizontal string trimmer reduces labor costs, increases peach size 2PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 1PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 2PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 3PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 4PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 5Hangovers May Be Tougher for Migraine Sufferers 59737 1Evosys a Major Player in the Oracle E Business Suite Implementation Support and Consultancy Services Domain has Recently Been Awarded Oracles Certi 59733 1Evosys a Major Player in the Oracle E Business Suite Implementation Support and Consultancy Services Domain has Recently Been Awarded Oracles Certi 59733 2Evosys a Major Player in the Oracle E Business Suite Implementation Support and Consultancy Services Domain has Recently Been Awarded Oracles Certi 59733 3
... the hottest fields in research, investment, and manufacturing. ... Revolution." , But how many Americans ... feel that the potential benefits of nanotechnology will ... monitor the safety of new technologies? And will ...
... the most popular building blocks of nanotechnology and is ... architectures. For the most part, DNA is looked upon ... from the bottom up. Now a team of researchers ... standard microfabrication and lithography tools to form features such ...
... paracetamol is used to soothe every kind of pain, from ... medicine is one of the most used nowadays. However, research ... the University of Granada showed that taking paracetamol ... vitro studies. , Author of this work is Olga Garca ...
Other Biology News:Nanotechnology: What's that? 2Unmasking DNA 2Paracetamol, one of most used analgesics, could slow down bone growth 2
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
... The ideal modular cleanroom for biological ... that require cleanliness (to Class 10/ISO ... precision-joined to create ultra-smooth surfaces that ... disinfect. One-inch radius corners simplify cleaning. ...
... These versatile enclosures ... with nitrogen or other ... a low-humidity environment. HEPA ... and ionization modules also ...
... The ideal modular cleanroom for biological ... that require cleanliness (to Class 10/ISO ... precision-joined to create ultra-smooth surfaces that ... disinfect. One-inch radius corners simplify cleaning. ...
Biology Products: